Vontobel Holding
ADAP

Vontobel Holding’s Adaptimmune Therapeutics ADAP Stock Holding History

Vontobel Holding’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,000
Closed -$23.2K – 1088
2024
Q4 		$23.2K Hold
43,000
– – ﹤0.01% 1089
2024
Q3 		$40.9K Buy
43,000
+30,000
+231% +$34K ﹤0.01% 1067
2024
Q2 		$12.6K Sell
13,000
-10,000
-43% -$11K ﹤0.01% 1066
2024
Q1 		$36.3K Buy
+23,000
New +$27.8K ﹤0.01% 1061
2021
Q4 		– Sell
-103,000
Closed -$533K – 1041
2021
Q3 		$533K Buy
103,000
+3,000
+3% +$13.5K ﹤0.01% 773
2021
Q2 		$426K Hold
100,000
– – ﹤0.01% 810
2021
Q1 		$531K Buy
100,000
+30,000
+43% +$172K ﹤0.01% 655
2020
Q4 		$377K Buy
+70,000
New +$380K ﹤0.01% 739

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vontobel Holding's ADAP Position: Q1 2025 in Review

Vontobel Holding sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 43,000 shares — an estimated $23.2K sold.

Vontobel Holding first reported a position in ADAP in Q4 2020 and held it in 8 quarters. The position peaked at $533K in Q3 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Vontobel Holding reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vontobel Holding sold 43,000 Adaptimmune Therapeutics shares in Q1 2025, an estimated $23.2K.
  • Vontobel Holding first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 8 quarters.
  • Vontobel Holding's Adaptimmune Therapeutics position peaked at $533K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Vontobel Holding's 13F filing for Q1 2025, filed 28 Apr 2025.